Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics director Nancy C. Andrews was granted a stock option on 09/22/2025 to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) common stock at an exercise price of $23.67 per share. The option award appears in a Form 4 filed on 09/24/2025 and is reported as a direct beneficial holding of 18,000 underlying shares after the transaction. The disclosure states the option will vest in nine equal monthly tranches (1/9 each month) with the first tranche vesting on October 1, 2025, subject to continued service. The instrument lists a date of exercisability/expiration of 09/21/2035 and zero listed cash paid on exercise in the table.
Maze Therapeutics director Richard H. Scheller reported a sale of company stock on September 15, 2025. The filing shows 20,744 shares of Maze common stock were disposed of in multiple transactions at a weighted average price of $22.3696 per share, with individual trade prices ranging from $22.14 to $22.585. After the reported sale the reporting person beneficially owned 0 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on September 16, 2025. The filer is identified as a director of Maze Therapeutics and the transaction is recorded as a non-derivative sale of common stock.
Maze Therapeutics reported a private placement of pre-funded warrants to raise capital and provided related registration rights and disclosures. The company sold pre-funded warrants to purchase up to 5,231,090 shares of common stock at a purchase price of $16.249 per pre-funded warrant, with each warrant exercisable for $0.001 per share and not expiring. The company agreed to file a registration statement for resale of the shares within 60 days of closing and to use reasonable best efforts to have it declared effective within 75 days of initial filing. The filing states the securities were sold without registration and only to accredited investors for investment purposes. Exhibits include forms of the warrant, purchase agreement and registration rights agreement, plus press releases announcing the private placement and MZE782 data dated September 11, 2025. The filing also contains standard forward-looking statement language identifying programs MZE829 and MZE782 and listing development, regulatory, funding and macroeconomic risks.
Tahir Misbah, Chief Financial Officer of Maze Therapeutics, Inc. (MAZE), was granted a stock option for 325,000 shares with an exercise price of $15.32. The Form 4 reports the option award dated 09/02/2025 and shows 325,000 shares beneficially owned following the transaction as a direct holding. The option includes a vesting schedule: 1/4 of the award vests on September 2, 2026, then 1/48th of the total award vests monthly thereafter, subject to continued service. The filing is signed by an attorney-in-fact on behalf of the reporting person and reports the transaction under Section 16.
Tahir Misbah, identified as Chief Financial Officer and a director of Maze Therapeutics, Inc. (Ticker: MAZE), submitted an initial Form 3 reporting his beneficial ownership status. The filing states no securities are beneficially owned by the reporting person. The form was executed through an attorney-in-fact signature on the submitted document.
Maze Therapeutics announced the appointment of Misbah Tahir as Chief Financial Officer and principal financial officer, effective September 2, 2025. The company disclosed key compensation terms in an offer letter: an initial annual base salary of $500,000, an annual discretionary bonus opportunity up to 40% of base salary, a one-time sign-on bonus of $50,000 (subject to clawback if service is under one year), and an equity option to purchase up to 325,000 shares that vests 25% after one year and then 1/48th monthly thereafter. The filing notes the appointment relates to Maze's Form 10-Q for the quarter ending September 30, 2025.
Maze Therapeutics director Neil Exter reported acquisition of an option to purchase 16,000 shares of Maze Therapeutics, Inc. (MAZE). The option has an exercise price of $13.35 and was reported with a transaction date of 08/17/2025. The option becomes exercisable beginning 08/16/2035 per the table, and 16,000 underlying shares are associated with the award. The filing explains the option vests monthly after an initial partial vesting of 1/16th on March 3, 2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Frazier Life Sciences funds report material holdings in Maze Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 3,352,915 shares, equal to 7.7% of the outstanding class. Other reporting entities include Frazier Life Sciences Public Overage Fund, L.P. with 989,351 shares (2.3%), Frazier Life Sciences X, L.P. with 75,982 shares (0.2%), and Frazier Life Sciences XI, L.P. with 149,026 shares (0.3%). Percentages are calculated using 43,797,166 shares outstanding as reported by the issuer.
The filing clarifies voting and dispositive arrangements: several entities report shared voting and dispositive power over the disclosed shares, and James N. Topper and Patrick J. Heron share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The Statement expressly corrects prior attributions and overstatements of beneficial ownership for certain members and includes a certification that the securities are not held for the purpose of changing or influencing control of the issuer.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 2,625,089 shares of Maze Therapeutics common stock, representing 6.0% of the outstanding class. The filing shows no sole voting or dispositive power and discloses shared voting and dispositive power over those shares, indicating the position is managed collectively rather than controlled by a single entity. The reporting person is classified as an investment adviser (IA, HC), and the filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.
The filing further identifies indirect subsidiaries as the operating vehicles that acquired the securities and includes a power of attorney authorizing firm personnel to file ownership reports on the company’s behalf.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report joint beneficial ownership of 3,948,910 shares of Maze Therapeutics common stock, which the statement says represents 9.02% of the outstanding common shares. The holders report shared voting and shared dispositive power over those shares and no sole voting or dispositive power.
The ownership percentage is calculated from 43,797,166 shares outstanding per the issuer's public disclosures. The filing includes a certification that the shares were not acquired to change or influence control of the issuer and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.